Drug intelligence / Profile preview

PSB102

Development stage: Unknown
Lead developer: Qilu Puget Sound Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PSB102 is an Fc-enhanced humanized type II anti-CD20 IgG1 monoclonal antibody. It is a novel biological entity that targets B-cells by binding to the CD20 antigen. PSB102 is a component of the combination product PSB202, which also includes PSB107 (a humanized anti-CD37 IgG1). PSB202 is designed to work as a single product, with its two components enabling dual target-specific antibody-directed cell killing of B-cells. PSB102 is being developed by Qilu Puget Sound Biotherapeutics (dba Sound Biologics).

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on PSB102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB102.

Explore the full profile